Johnson & Johnson $JNJ Stake Raised by Colton Groome Financial Advisors LLC

Colton Groome Financial Advisors LLC lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 219.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 7,145 shares of the company’s stock after purchasing an additional 4,906 shares during the quarter. Colton Groome Financial Advisors LLC’s holdings in Johnson & Johnson were worth $1,892,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Eleva Capital SAS purchased a new position in shares of Johnson & Johnson in the third quarter valued at approximately $1,442,000. Baker Tilly Wealth Management LLC increased its stake in Johnson & Johnson by 4.7% during the 3rd quarter. Baker Tilly Wealth Management LLC now owns 10,423 shares of the company’s stock worth $2,759,000 after buying an additional 469 shares during the period. Ferguson Wellman Capital Management Inc. lifted its holdings in Johnson & Johnson by 41.0% during the 3rd quarter. Ferguson Wellman Capital Management Inc. now owns 666,675 shares of the company’s stock worth $176,495,000 after buying an additional 193,905 shares in the last quarter. Adelphi Trust Co grew its stake in shares of Johnson & Johnson by 5.1% in the third quarter. Adelphi Trust Co now owns 1,950 shares of the company’s stock worth $516,000 after acquiring an additional 95 shares in the last quarter. Finally, Eastern Bank grew its stake in shares of Johnson & Johnson by 105.9% in the third quarter. Eastern Bank now owns 299,306 shares of the company’s stock worth $79,238,000 after acquiring an additional 153,938 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on JNJ. TD Cowen increased their price objective on Johnson & Johnson from $250.00 to $300.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Johnson Rice restated a “buy” rating on shares of Johnson & Johnson in a report on Monday, August 3rd. Royal Bank Of Canada lifted their price objective on Johnson & Johnson from $287.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday. JPMorgan Chase & Co. boosted their price objective on Johnson & Johnson from $270.00 to $285.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 29th. Finally, Weiss Ratings raised shares of Johnson & Johnson from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, July 24th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $276.22.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer Taubert sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the transaction, the executive vice president directly owned 194,451 shares in the company, valued at approximately $51,210,615.36. This trade represents a 7.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Vanessa Broadhurst sold 23,054 shares of the company’s stock in a transaction on Monday, July 20th. The shares were sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the completion of the sale, the executive vice president owned 23,003 shares of the company’s stock, valued at approximately $5,779,963.81. This trade represents a 50.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 87,569 shares of company stock valued at $23,064,544. 0.16% of the stock is currently owned by insiders.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson’s diversified pharmaceutical, medical-device and consumer-health businesses, along with new drug launches and sales growth, give it an advantage over Pfizer despite Pfizer’s lower valuation and higher dividend yield. Pfizer vs. J&J: Comparing Growth, Patent Risks and Valuation
• Positive Sentiment: Analysts and financial commentators continue to view J&J as a defensive dividend holding: demand for healthcare products may remain resilient during an economic downturn, supporting its long record of dividend increases. Looking for a Dividend Stock That Can Weather a Downturn?
• Neutral Sentiment: J&J and Procter & Gamble trade at similar valuations, with the investment comparison centered on which company can sustain dividend growth over the next two decades. The discussion supports J&J’s income-investment appeal but does not introduce a new company-specific catalyst. Johnson & Johnson or Procter & Gamble
• Neutral Sentiment: Johnson & Johnson is expected to report earnings on October 13. Although earnings are projected to grow, one analysis says the company lacks the usual combination of estimate revisions and other factors associated with a likely earnings beat, potentially limiting pre-earnings optimism. Johnson & Johnson Earnings Expected to Grow
• Negative Sentiment: Investors remain concerned that a roughly $4 billion revenue patent cliff in 2027 could pressure growth. The key issue is whether J&J’s replacement pipeline and new launches can offset the loss of exclusivity, making the upcoming earnings report more important than the quarterly EPS result alone. Why a $4 Billion 2027 Patent Cliff Matters

Johnson & Johnson Stock Performance

NYSE JNJ traded up $1.62 during trading hours on Tuesday, hitting $254.55. The company had a trading volume of 2,347,308 shares, compared to its average volume of 7,977,202. The business has a 50 day moving average of $266.10 and a 200-day moving average of $248.51. The company has a market cap of $613.44 billion, a PE ratio of 29.49, a price-to-earnings-growth ratio of 2.52 and a beta of 0.21. Johnson & Johnson has a 1-year low of $182.94 and a 1-year high of $281.07. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The business had revenue of $25.31 billion for the quarter, compared to analysts’ expectations of $25.06 billion. During the same quarter in the previous year, the firm earned $2.77 earnings per share. The business’s revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, equities research analysts expect that Johnson & Johnson will post 11.54 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were paid a $1.34 dividend. The ex-dividend date was Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a yield of 2.1%. Johnson & Johnson’s payout ratio is currently 62.11%.

Johnson & Johnson Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.